NXGLW: the cash flow

MyFinsight

Home Blog About

MyFinsight

Making company financials insightful for everyone

About
Blog
Privacy Policy
Contact

Follow Us

X.com
Thread
Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash

$175K

Unit: Thousand (K) dollars

Positive Cash Flow Breakdown

Negative Cash Flow Breakdown

Cash Flow

2026-06-30

2026-03-31

2025-12-31

2025-09-30

Realized gain on investment in marketable securities

-

-

0

0

Net loss attributable to nexgel stockholders

-

-

-

-653

Change in fair value of contingent consideration

-

-

0

-

Income (loss) attributable to non-controlling interest in joint venture

-

-

-

6

Net loss

-3,607

-871

-2,893

-

Partnership advance

-

-135

811

-80

Depreciation and amortization

827

99

112

113

Share-based compensation and restricted stock vesting

119

143

156

205

Amortization of right-of-use asset

155

73

290

-

Net changes in operating lease assets and liabilities

-

-

-

0

Amortization of debt discount

1,903

11

-

-

Changes in fair value of warrant liability and warrant modification expense

-1,436

-

-6

-8

Gain in spin-off of nexgelrx

-

-

162

-

Loss on issuance of convertible debt

422

-

-

-

Accounts receivable, net

416

-11

-166

86

Inventory

14

152

92

198

Prepaid expenses and other assets

491

95

-390

23

Accounts payable

345

479

-72

-31

Accounts payable related party

-29

38

145

-26

Accrued expenses and other current liabilities

284

-32

-70

-4

Partnership advance

248

-

-

-

Operating lease liability

-144

-73

-260

-

Deferred revenue

-2

-

-178

0

Net cash used in operating activities

-2,197

-504

281

-785

Investment in subsidiary

-

-

0

-

Proceeds from sales of marketable securities

-

-

0

0

Net cash paid for asset acquisition

-

-

-

0

Capital expenditures

85

-

-

-

Purchases of equipment

-

-

68

-

Capital expenditures

-

-19

-

8

Investment in bionx (license agreement)

6,502

-

-

-

Net cash used in investing activities

-6,578

-9

-40

-8

Proceeds from non-controlling interest

-

-

0

-

Proceeds from margin line of credit

-

-

0

0

Investment by joint venture partner

-

-

-

0

Change in contingent consideration liability

-

-

-

0

Proceeds from stada (note 17)

-

-

-

1,000

Proceeds from rights offering

-

-

-92

1,055

Stock issuance costs

-

-

-

92

Payment of contingent consideration

-

-

-1

0

Proceeds from convertible notes payable, net

8,585

1,618

-

-

Principal payment on financing lease liability

20

16

16

14

Financing costs

182

-

-

-

Principal payments of notes payable

24

25

26

23

Net cash provided by (used in) financing activities

8,359

1,577

-1,041

1,926

Net increase (decrease) in cash ()

-

-

333

-

Net increase (decrease) in cash

-416

1,064

-800

51

Cashand restricted cash beginning of period

2,122

1,058

1,858

1,807

Cash and restricted cash end of period

1,706

2,122

1,058

1,858

Increase in cash

175

-

-

-

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

NEXGEL, INC. (NXGLW)

NEXGEL, INC. (NXGLW)